MedTrace Logo

Electrical Brain Stimulation and Pharmacological Treatments in Autism Spectrum Disorder

NCT05491720 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2023-11-07

No results posted yet for this study

Summary

This project aims to comparing the effectiveness of transcranial direct current stimulation with common pharmacological treatments on behavioral problems and cognitive deficits of children with autism spectrum disorder

Conditions

Interventions

DRUG

RisperiDONE 1 MG/ML

Patients will receive two daily Risperidone 1 mg tablets (Sobhan Pharmaceutical Company) for 10 consecutive days

DEVICE

transcranial direct current stimulation

Patients will receive 10 sessions of 20 minutes of 1.5 mA electrical stimulation on consecutive days

DRUG

Placebo

Patients will receive placebo tablet (Galenus pharmaceutical company)

DEVICE

sham transcranial direct current stimulation

Patients will receive 10 sessions of 20 minutes of sham electrical stimulation on consecutive days

Sponsors & Collaborators

  • Ardabil University of Medical Sciences

    collaborator OTHER

  • Leibniz Research Centre for Working Environment and Human Factors

    collaborator OTHER

  • University of Tehran

    collaborator OTHER

  • The National Brain Mapping Laboratory (NBML)

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
7 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-15
Primary Completion
2022-03-15
Completion
2022-08-03

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05491720 on ClinicalTrials.gov